Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Thermo Fisher Scientific Inc. pages available for free this week:
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Geographic Areas
- Enterprise Value (EV)
- Capital Asset Pricing Model (CAPM)
- Net Profit Margin since 2005
- Operating Profit Margin since 2005
- Return on Assets (ROA) since 2005
- Debt to Equity since 2005
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Thermo Fisher Scientific Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Short-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
The analysis of short-term activity ratios reveals a period of initial efficiency gains in inventory management followed by a stabilization phase, alongside a gradual decline in receivables collection efficiency. The overall operational flow demonstrates volatility in working capital utilization and payment strategies, though the cash conversion cycle has remained relatively contained compared to early 2022 levels.
- Inventory Management Efficiency
- Inventory turnover showed a consistent upward trend from 3.87 in April 2022 to a peak of 5.06 in December 2023. This improvement is mirrored in the average inventory processing period, which decreased from 94 days to a low of 72 days in December 2023. From 2024 through March 2026, these metrics stabilized, with the turnover ratio fluctuating between 4.47 and 5.06 and the processing period averaging approximately 75 to 82 days.
- Receivables and Collection Performance
- A moderate decline in receivables turnover is observed, moving from a peak of 5.76 in October 2022 to 4.91 by March 2026. Correspondingly, the average receivable collection period has gradually lengthened from 63 days in October 2022 to 74 days by the end of the period. This trend suggests a slight slowdown in the conversion of credit sales into cash.
- Payables and Liquidity Strategy
- Payables turnover exhibits significant volatility, peaking at 10.82 in July 2023 before trending downward to 8.00 by March 2026. The average payables payment period followed a similar fluctuating pattern, dropping to a minimum of 34 days in July 2023 and extending to 50 days by December 2025. This indicates shifting strategies regarding the timing of obligations to suppliers.
- Operating and Cash Conversion Cycles
- The operating cycle contracted from 164 days in April 2022 to a low of 142 days in December 2023, before stabilizing between 142 and 156 days. The cash conversion cycle experienced a similar contraction, moving from 118 days to a periodic low of 97 days (seen in December 2022 and December 2024), ending at 103 days in March 2026. These shifts indicate that while inventory movement improved, the gains were partially offset by slower receivable collections.
- Working Capital Utilization
- Working capital turnover demonstrated high instability throughout the period. After a sharp spike to 10.13 in April 2023, the ratio entered a general downward trend, reaching a low of 3.30 in December 2025. This volatility suggests significant fluctuations in the relationship between net working capital and annual revenue generation.
Turnover Ratios
Average No. Days
Inventory Turnover
| Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Cost of revenues | |||||||||||||||||||||||
| Inventories | |||||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Inventory turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Inventory Turnover, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q1 2026 Calculation
Inventory turnover
= (Cost of revenuesQ1 2026
+ Cost of revenuesQ4 2025
+ Cost of revenuesQ3 2025
+ Cost of revenuesQ2 2025)
÷ Inventories
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of operating activity reveals a general improvement in inventory management efficiency from early 2022 through late 2023, followed by a period of volatility and eventual stabilization through early 2026.
- Inventory Turnover Trends
- A consistent upward trend in the inventory turnover ratio is observed from April 2022 (3.87) to December 2023, where it reached a peak of 5.06. This progression indicates an increase in the velocity at which inventory was processed and sold. Following this peak, the ratio experienced a period of fluctuation, dipping to a low of 4.47 in June 2025 before recovering to 4.87 by March 2026.
- Inventory Level Dynamics
- Inventory levels remained relatively stable, fluctuating between a high of 5.745 billion USD in September 2025 and a low of 4.978 billion USD in December 2024. The periods of highest turnover ratios generally correlate with lower average inventory holdings, specifically in late 2023 and late 2024, suggesting effective lean inventory management during those intervals.
- Cost of Revenues Correlation
- The cost of revenues exhibited relative stability, typically ranging between 6.1 billion USD and 6.6 billion USD per quarter. A notable peak occurred in December 2024 at 7.204 billion USD, which, combined with the period's lowest inventory level of 4.978 billion USD, contributed to a heightened turnover ratio of 5.06. This suggests that spikes in turnover were driven both by increased throughput and strategic reductions in stock levels.
- Operating Efficiency Summary
- The overall movement of the turnover ratio suggests a transition from a lower efficiency baseline in 2022 to a higher, more volatile operational standard. Despite the mid-2025 decline, the ending ratio of 4.87 indicates a sustained improvement in operational efficiency compared to the start of the observed period.
Receivables Turnover
| Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||
| Accounts receivable, less allowances | |||||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Receivables turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Receivables Turnover, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q1 2026 Calculation
Receivables turnover
= (RevenuesQ1 2026
+ RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025)
÷ Accounts receivable, less allowances
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of receivables turnover from April 2022 through March 2026 reveals a gradual decline in the efficiency of credit collection, characterized by a steady increase in the balance of accounts receivable relative to revenue growth.
- Receivables Turnover Trend
- The turnover ratio experienced an initial increase, peaking at 5.76 in October 2022. However, this peak was followed by a long-term downward trajectory. By the end of the observed period in March 2026, the ratio declined to 4.91, marking a systemic reduction in the frequency with which the company converts its receivables into cash.
- Revenue and Asset Correlation
- Revenues remained relatively stable, fluctuating primarily between 10.3 billion and 12.2 billion US dollars. In contrast, accounts receivable, less allowances, demonstrated a consistent upward trend, rising from 7.889 billion US dollars in April 2022 to 9.204 billion US dollars by March 2026. The lack of a proportional increase in revenue to match the growth in receivables is the primary driver behind the deteriorating turnover ratio.
- Operational Implications
- The decline in the turnover ratio suggests a lengthening of the average collection period. The transition from a peak of 5.76 to a low of 4.91 indicates that credit is remaining outstanding for longer durations, which may point to a loosening of credit policies, a shift in customer payment behavior, or an increase in the volume of sales conducted on credit terms.
- Recent Performance Period
- During the 2025 and early 2026 period, the turnover ratio consistently remained below 5.1, reaching its lowest points of 4.91. Despite a significant revenue spike in December 2024 (12.215 billion US dollars), the corresponding increase in receivables prevented a meaningful recovery in the turnover ratio, confirming a persistent trend of slowing receivable velocity.
Payables Turnover
| Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Cost of revenues | |||||||||||||||||||||||
| Accounts payable | |||||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Payables turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Payables Turnover, Competitors2 | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q1 2026 Calculation
Payables turnover
= (Cost of revenuesQ1 2026
+ Cost of revenuesQ4 2025
+ Cost of revenuesQ3 2025
+ Cost of revenuesQ2 2025)
÷ Accounts payable
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of payables turnover reveals a pattern of cyclical volatility coupled with a long-term decelerating trend in payment velocity between April 2022 and March 2026.
- Seasonal Cyclicality
- A recurring decline in the payables turnover ratio is observed during the fourth quarter of each year. Notable dips occurred in December 2022 (7.67), December 2023 (8.97), December 2024 (8.18), and December 2025 (7.27). These declines correlate with consistent peaks in accounts payable balances, suggesting a year-end accumulation of short-term liabilities.
- Long-term Turnover Trend
- Following a period of increased efficiency that peaked in July 2023 with a ratio of 10.82, a general downward trajectory is evident. The ratio trended lower through 2024 and 2025, reaching a series low of 7.27 by December 31, 2025. This downward movement indicates an extension of the average time taken to settle obligations with suppliers.
- Operational Correlation
- The cost of revenues remained relatively stable, generally oscillating between 6.1 billion and 6.5 billion US dollars, with a significant peak of 7.2 billion in December 2025. The fact that the turnover ratio reached its lowest point (7.27) during the same period as the highest cost of revenues suggests that the increase in operating expenditures was accompanied by a strategic increase in accounts payable to manage cash flow.
- Working Capital Implications
- The transition from a turnover ratio of approximately 10.0 in mid-2023 to 8.00 by March 2026 reflects a shift in working capital management. The slower turnover rate suggests a greater reliance on supplier financing, effectively increasing the company's interest-free credit period.
Working Capital Turnover
| Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Current assets | |||||||||||||||||||||||
| Less: Current liabilities | |||||||||||||||||||||||
| Working capital | |||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Working capital turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q1 2026 Calculation
Working capital turnover
= (RevenuesQ1 2026
+ RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025)
÷ Working capital
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The operational efficiency regarding working capital utilization exhibits significant volatility over the period from early 2022 to early 2026. While revenues remained relatively stable, fluctuations in working capital levels drove substantial variations in the turnover ratio, indicating shifting balances between current assets and current liabilities.
- Working Capital Trends
- Working capital levels demonstrated a general upward trajectory, rising from 6,706 million USD in April 2022 to a peak of 13,518 million USD in December 2025. This growth was characterized by extreme volatility, with sharp contractions occurring in April 2023 (4,325 million USD) and September 2025 (7,407 million USD), both of which were followed by rapid increases.
- Revenue Stability
- Revenues remained remarkably consistent, fluctuating within a narrow corridor between 10,345 million USD and 12,215 million USD. The absence of a strong growth trend in revenue, contrasted with the expanding base of working capital, suggests that the changes in the turnover ratio are primarily a function of balance sheet management rather than sales expansion.
- Working Capital Turnover Analysis
- The turnover ratio fluctuated between a peak of 10.13 in April 2023 and a low of 3.30 in December 2025. The spike in early 2023 was driven by a significant reduction in working capital rather than a surge in revenue. For much of 2023 and 2024, the ratio experienced a downward trend, frequently falling below 5.0, which indicates a decline in the efficiency of working capital in generating sales. However, a recovery is observed in the final quarters, with the ratio returning to levels between 5.87 and 5.90 by March 2026, coinciding with a reduction in working capital holdings.
Average Inventory Processing Period
| Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||
| Inventory turnover | |||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||
| Average inventory processing period1 | |||||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q1 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals a significant improvement in inventory management efficiency from early 2022 through late 2023, followed by a period of relative stabilization through March 2026.
- Inventory Turnover Trends
- A sustained upward trajectory in the inventory turnover ratio is observed from April 2022 (3.87) to December 2023, where it reached a peak of 5.06. This indicates an acceleration in the rate at which inventory is sold and replaced. Following this peak, the ratio entered a phase of moderate volatility, fluctuating between a low of 4.47 in June 2025 and 5.06 in December 2024, eventually settling at 4.87 by March 2026.
- Average Inventory Processing Period
- The average inventory processing period demonstrates a corresponding inverse relationship with turnover. An initial downward trend is evident, with the period decreasing from 94 days in April 2022 to a minimum of 72 days by December 2023. This reduction signifies a more streamlined movement of goods through the operating cycle. From March 2024 onward, the processing period stabilized within a range of 72 to 82 days, concluding at 75 days in the final observed quarter.
- Operational Efficiency Synthesis
- The overall trend suggests an optimization of working capital management. The transition from a 94-day processing cycle to a stabilized cycle averaging approximately 75 to 80 days represents a meaningful reduction in the duration that capital remains tied up in inventory. The stabilization observed throughout 2024 and 2025 indicates that a new operational baseline for inventory throughput has been established.
Average Receivable Collection Period
| Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||
| Receivables turnover | |||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||
| Average receivable collection period1 | |||||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q1 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals a gradual deterioration in the efficiency of receivables management over the period from April 2022 to March 2026. While a period of improved collection efficiency occurred in late 2022, the subsequent years are characterized by a steady increase in the time required to convert credit sales into cash.
- Receivables Turnover Ratio
- The turnover ratio exhibited an initial upward trend, peaking at 5.76 in October 2022. Following this peak, a general downward trajectory is observed. The ratio fluctuated between 5.53 and 5.03 throughout 2023 and 2024, eventually reaching its lowest recorded value of 4.91 by March 2026. This decline indicates a reduction in the frequency with which the average accounts receivable balance is collected during the period.
- Average Receivable Collection Period
- The collection period displays a strong inverse correlation with the turnover ratio. A minimum collection period of 63 days was achieved in October 2022, representing the peak of operational efficiency for this metric. Subsequently, the collection timeframe lengthened, stabilizing around 70 days through much of 2023 before entering a sustained increase. By March 2026, the collection period reached 74 days, reflecting a slowing of cash inflows relative to the 2022 low.
The simultaneous decline in the turnover ratio and the extension of the collection period suggest a weakening of the credit-to-cash cycle. The increase from a 63-day low to a 74-day high indicates a potential shift in customer payment behavior or a modification in credit terms, which may result in increased working capital requirements to sustain operations.
Operating Cycle
| Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||
| Average inventory processing period | |||||||||||||||||||||||
| Average receivable collection period | |||||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Operating cycle1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Operating Cycle, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q1 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =
2 Click competitor name to see calculations.
The operating cycle demonstrates an initial period of contraction followed by a phase of relative stabilization with minor fluctuations. Between April 2022 and December 2023, the total duration required to convert inventory into cash decreased from 164 days to 142 days, suggesting a significant improvement in short-term operational efficiency. From January 2024 through March 2026, the cycle remained largely range-bound, fluctuating between a low of 142 days and a peak of 156 days, ultimately settling at 149 days.
- Average Inventory Processing Period
- A notable downward trend is observed in the first half of the analyzed period, with the processing time falling from 94 days in April 2022 to a low of 72 days by December 2023. Following this improvement, the period entered a phase of volatility, peaking at 82 days in June 2025 before returning to 75 days by March 2026. This indicates that while inventory management became more efficient overall compared to 2022, it has since encountered periodic increases in processing time.
- Average Receivable Collection Period
- The collection period exhibited a slight initial decline, reaching a minimum of 63 days in October 2022. However, a gradual and consistent upward trend is observable from April 2023 (66 days) through March 2026 (74 days). This steady increase suggests a gradual slowing in the conversion of accounts receivable into cash, which has acted as a counterweight to the gains made in inventory processing.
- Operating Cycle Dynamics
- The overall operating cycle was primarily driven by inventory efficiencies during 2022 and 2023, which led to a 22-day reduction in the total cycle. In the latter period, the expansion of the receivable collection period began to offset inventory gains, leading to a moderate increase in the operating cycle during 2025. The final observation of 149 days represents a net improvement of 15 days over the initial April 2022 baseline, though the trend indicates a slight erosion of those gains in the final quarters.
Average Payables Payment Period
| Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||
| Payables turnover | |||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||
| Average payables payment period1 | |||||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q1 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals a fluctuating trend in the management of accounts payable, characterized by an initial phase of accelerated payment cycles followed by a gradual extension of credit terms toward the end of the observed period.
- Payables Turnover Trends
- The payables turnover ratio exhibited significant volatility, initially rising from 7.96 in April 2022 to a peak of 10.82 in July 2023. This upward movement indicates a period of more frequent settlement of obligations to suppliers. Following this peak, the ratio entered a general downward trajectory, reaching its lowest point of 7.27 in December 2025, before stabilizing at 8.00 by March 2026.
- Average Payables Payment Period Analysis
- The average duration for settling payables mirrored the turnover ratio inversely. The payment window contracted from 46 days in April 2022 to a minimum of 34 days in July 2023, signaling a phase of rapid liquidation of short-term liabilities. Subsequently, the payment period expanded consistently, increasing to 45 days by December 2024 and reaching a maximum of 50 days in December 2025. This extension suggests a strategic shift toward optimizing working capital by utilizing supplier credit for longer durations.
- Operational Correlation
- A strong inverse correlation is observed between the turnover ratio and the payment period. The transition from a 34-day payment cycle in mid-2023 to a 50-day cycle by late 2025 reflects an intentional broadening of the payment window. The data indicates that while the organization prioritized rapid settlement during the 2022-2023 period, it transitioned toward a more extended payment strategy through 2024 and 2025.
Cash Conversion Cycle
| Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||
| Average inventory processing period | |||||||||||||||||||||||
| Average receivable collection period | |||||||||||||||||||||||
| Average payables payment period | |||||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Cash conversion cycle1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Cash Conversion Cycle, Competitors2 | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q1 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + – =
2 Click competitor name to see calculations.
The operational efficiency metrics indicate a general contraction and subsequent stabilization of the cash conversion cycle over the analyzed period, reflecting shifts in inventory management and supplier payment strategies.
- Average Inventory Processing Period
- A notable downward trend is observed from April 2022, where the period stood at 94 days, reaching a low of 72 days by December 2023. Following this optimization phase, the period experienced a moderate increase, peaking at 82 days in June 2025, before stabilizing at 75 days by March 2026. This suggests an initial improvement in inventory turnover that was later balanced by fluctuating operational requirements.
- Average Receivable Collection Period
- The collection period remained relatively consistent, oscillating within a narrow range. After a decrease to 63 days in October 2022, the duration gradually trended upward, stabilizing between 68 and 74 days from March 2024 through March 2026. This slight increase indicates a marginal slowing in the conversion of accounts receivable into cash toward the end of the period.
- Average Payables Payment Period
- Significant volatility is evident in the payment of payables. The period declined from 46 days in April 2022 to a minimum of 34 days in July 2023. Subsequently, a reversal occurred, with the period extending to 50 days by December 2025 before settling at 46 days in March 2026. This extension in the latter half of the timeline suggests a strategic utilization of supplier credit to enhance short-term liquidity.
- Cash Conversion Cycle
- The overall cash conversion cycle decreased from 118 days in April 2022 to a low of 97 days in December 2022, with a similar low reached in December 2024. The cycle concluded at 103 days in March 2026. The reduction in the cycle was primarily driven by improved inventory processing in the early stages, while later fluctuations were influenced by the interplay between lengthening receivable collections and extended payable periods.